Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014
-
Upload
ahmed-albeyaly -
Category
Documents
-
view
237 -
download
4
Transcript of Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014
![Page 1: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/1.jpg)
By : Shereef MamdouhBy : Shereef MamdouhAssistant lecturer of internal Assistant lecturer of internal
medicinemedicineNephrology departmentNephrology department
![Page 2: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/2.jpg)
Elshahat saad abd dayem, 44ys old male patient, from Rashid, smoker, not married
A CRF patient on HD since 15ys15ys Complaining of :
Generalized Bony aches since 5ys5ys
Bilateral shoulder, hip pain since 3ys3ys
Low back pain since 3ys3ys
![Page 3: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/3.jpg)
20 years ago patient presented by generalized oedema, HTN
Investigations revealed nephrotic range proteinuria and renal impairment, Renal biopsy was done and revealed MPGN , lab investigations revealed no secondary cause and patient diagnosed as primary MPGNprimary MPGN
![Page 4: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/4.jpg)
Treatment started in the form of corticosteroidscorticosteroids and cyclophosphamidecyclophosphamide pulse for 3m, then patient lost follow up
5 years later, patient developed ESRD and started HD HD 3 times per week, 4hrs a session, QB 300-350 ml/min
Patient was compliant and did not miss HD sessions with Kt/V > 1.2Kt/V > 1.2
![Page 5: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/5.jpg)
5ys ago patient started to complain of gradual onset of generalized bony aches moderatemoderate in intensity with fairfair response to analgesia
No history of pruritus, muscle weakness
![Page 6: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/6.jpg)
Patient was conscious, alert, average Wt and Ht
Patient was vitally stable
No signs of volume overload
No signs of CTS
![Page 7: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/7.jpg)
Investigations revealed Investigations revealed
CaCa 10.510.5 9.2 9.5
PhPh 44 4 4.3
PTHPTH 11051105 785 554
![Page 8: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/8.jpg)
US neck US neck revealed parathyroid parathyroid adenoma adenoma within the Rt
inferior parathyroid gland measuring 9X9 mm
![Page 9: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/9.jpg)
![Page 10: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/10.jpg)
Parathyroid sestamibi scanParathyroid sestamibi scan revealed failure to demonstrate any
hyperactive parathyroid gland
![Page 11: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/11.jpg)
![Page 12: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/12.jpg)
““patient diagnosed as patient diagnosed as 2ndry 2ndry
hyperparathyroidism, hyperparathyroidism, high turn over bone high turn over bone
disease”disease”
![Page 13: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/13.jpg)
Treatment guidelines Treatment guidelines of 2ndry of 2ndry
hyperparathyroidismhyperparathyroidism
![Page 14: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/14.jpg)
For dialysis patients, we suggest the following For dialysis patients, we suggest the following target goals: target goals:
Serum levels of phosphatephosphate should be maintained between 3.5 and 5.5 mg/dL
Serum levels of corrected total calcium corrected total calcium should be maintained between 8.4 and 9.5 mg/dL
Intact PTH Intact PTH (second generation PTH assay) should be maintained between 150 to 300 pg/mL
![Page 15: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/15.jpg)
A) A) Correction of Correction of serum phosphorusserum phosphorus
![Page 16: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/16.jpg)
“Moderate Ph restriction is recommended Moderate Ph restriction is recommended provided that this can be done without provided that this can be done without
compromising nutritional state”compromising nutritional state”
Avoid unnecessary dietary Ph unnecessary dietary Ph (Ph containing food additives, dairy
products, certain vegetables, processed food and cola)
Increase high-biologic-value protein high-biologic-value protein (meat and eggs)
![Page 17: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/17.jpg)
““Ph > 5.5Ph > 5.5””
Hypocalcemic patientsHypocalcemic patientsCalcium containing Ph binder (calcium acetate)
Normocalcemic patients Normocalcemic patients calcium containing or non-calcium containing P
binder (?? calciphylaxis, ? adynamic bone diseasecalciphylaxis, ? adynamic bone disease))
Hypercalcemic patientsHypercalcemic patientsNon calcium containing P binder (sevelamair 800-
1600mg tds, lanthanum 1500-3000mg/d)
![Page 18: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/18.jpg)
K “We suggest that, in patients with hyperphosphatemia, calcitriol or another vitamin D sterol should be reduced or stopped (2D).”
![Page 19: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/19.jpg)
Hemodialysis regimenHemodialysis regimen
Increased frequency
Extended HD
Nocturnal
![Page 20: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/20.jpg)
B) B) Correction of Correction of serum calciumserum calcium
![Page 21: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/21.jpg)
If Ca < 8.4 mg/dlIf Ca < 8.4 mg/dlgive 1-2 gm elemenlal Ca (Ca carbonate
contain 40% elemental Ca)
If Ca is in the target range If Ca is in the target range give 1 tablet of calcium carbonate 500
mg daily or eod
![Page 22: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/22.jpg)
If calcium level > 9.5 mg/dl If calcium level > 9.5 mg/dl
1.Stop Ca carbonate and acetate
2.Reduce or Stop Vit D
K “We recommend that, in patients with hypercalcemia, calcitriol or
another vitamin D sterol be reduced or stopped (1B).”
![Page 23: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/23.jpg)
C) C) Correction of Correction of PTHPTH
![Page 24: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/24.jpg)
Calcitriol, Alpha-1 calcidol :Calcitriol, Alpha-1 calcidol : hyper Ca, P > suppression of PTH
Newer synthetic vit D analogs : Newer synthetic vit D analogs : (doxercalciferol, paricalcitol)(doxercalciferol, paricalcitol)
suppression of PTH > hyper Ca, P
![Page 25: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/25.jpg)
Patient should fulfill the following criteriaPatient should fulfill the following criteria
Ca < 9.5 mg/dl P <5.5 mg /dl Ca X P product < 55 PTH > 150 pg/ml
DoseDose“Limit the dose of vit D because of risk of hyper Ca,P”
CalcitriolCalcitriol : 0.50.5 (physiological dose )- 22 mic after HD Alpha calcidol Alpha calcidol : 0.50.5 (physiological dose ) - 22 mic after HD Doxercalciferol Doxercalciferol : 11 (physiological dose )- 33 mic after HD Paricalcitol Paricalcitol : 22 (physiological dose )- 66 mic after HD
![Page 26: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/26.jpg)
CINACALCIT 30mg (up to 180 mg ) given if CINACALCIT 30mg (up to 180 mg ) given if patient fulfill the following criteriapatient fulfill the following criteria
PTH > 300 + PTH > 300 + Ca > 8.4 mg/dl +/- P > 5.5 mg/dl +/- Ca x P product > 55
““Cinacalcet should be stopped if Ca <7.5 Cinacalcet should be stopped if Ca <7.5 mg/dl”mg/dl”
![Page 27: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/27.jpg)
Indications for parathyroidectomy : Indications for parathyroidectomy :
Persistent PTH> 800 pg/ml + Persistent PTH> 800 pg/ml +
Severe spontaneous hypercalcemia
Progressive, debilitating hyperparathyroid bone disease
Intractable pruritus
Progressive extra skeletal calcification or calciphylaxis
Otherwise unexplained symptomatic myopathy.
![Page 28: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/28.jpg)
Ca 10.5
Ph 4
PTH 1105
![Page 29: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/29.jpg)
ThusThusWe started treatment in We started treatment in the form of cinacalcitthe form of cinacalcit ((mimparamimpara)) 30 mg once 30 mg once
dailydaily
![Page 30: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/30.jpg)
After 1m investigations wasAfter 1m investigations was
CaCa 10.510.5 9.29.2 9.5
PhPh 44 44 4.3
PTHPTH 11051105 785785 554
![Page 31: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/31.jpg)
Patient was maintained on : Patient was maintained on :
Alpha-1 calcidol (Alpha-1 calcidol (one alphaone alpha) ) 2 mic after each HD
Cinacalcit (Cinacalcit (mimparamimpara)) 30mg/d (we could not increase the dose because of financial problem )
![Page 32: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/32.jpg)
After 1m fu investigations wasAfter 1m fu investigations was
CaCa 10.510.5 9.29.2 9.59.5
PhPh 44 44 4.34.3
PTHPTH 11051105 785785 554554
![Page 33: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/33.jpg)
During the following period, During the following period, patient was maintained on :patient was maintained on :
Calcium carbonate Calcium carbonate 1 tab/d if Ca 8.4-9.5 mg/dl
Alpha-1 calcidol Alpha-1 calcidol 2 mic after each HD session iif Ca < 9.5 mg/dl, P < 5.5 mg/dl and Ca X P product <55
Cinacalcet Cinacalcet 30mg/d (some times is not available, and we can not increase the dose when needed)
![Page 34: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/34.jpg)
But PTH did not But PTH did not reach the targetreach the target
))150-300mg/dl150-300mg/dl((
![Page 35: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/35.jpg)
3ys ago patient start to complain of bilateral severesevere shoulder pain, not relieved not relieved by analgesia, this was associated with back pain
No symptoms of CTS
Beta 2 microglobulin done and was 70 mg/dl 70 mg/dl
![Page 36: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/36.jpg)
“NormalNormal” except for
Decreased bone mineral density
Fracture of both styloid process of ulna
![Page 37: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/37.jpg)
““we suspect we suspect DRA”DRA”
![Page 38: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/38.jpg)
![Page 39: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/39.jpg)
After 20 sessions After 20 sessions
Patient symptoms improved markedly
FU beta2 microglobulin was 8.7 8.7 mg/dl mg/dl
![Page 40: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/40.jpg)
Years
0 5 10 15 20
1ry MPGN ESRD2ry Hyperparathyroidism
DRA
Steroids, Steroids,
CPACPA Regular HDRegular HD
Cincalcet, Cincalcet,
Vit D,Vit D,
CaCa HDF
CaCa 10.510.5 9.29.2 9.59.5
PhPh 44 44 4.34.3
PTHPTH 11051105 785785 554554
APAP 601601520520
![Page 41: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/41.jpg)
Consider possibility of DRA in HD patients with intractable musculoskeletal pain, particularly if improvement is not matching with control of hyperparathyroid BMD
Online HDF is a promising approach to reduce Beta 2 microglobulin and improve features of DRA [[Role of dialysis technology Role of dialysis technology in removal of uraemic toxins. Hemodial Int in removal of uraemic toxins. Hemodial Int 2011;15: S49- 532011;15: S49- 53]]
![Page 42: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/42.jpg)
![Page 43: Case presentation Dr. Shereef Mamdouh. 2nd Annual Nephrology Meeting, CKD-MBD, NMGH, 28.10.2014](https://reader033.fdocuments.net/reader033/viewer/2022052508/559e072a1a28ab9c508b4688/html5/thumbnails/43.jpg)